Asebio, together with a delegation of partners, holds more than 500 meetings within the framework of Bio Chicago

The Association Spanish of Biocompanies (Asebio), along with 38 members, came last week to the 2010 BIO International Convention, considered the international show par excellence of the biotechnology sector, which took place from 3 to 6 may in Chicago (United States). The entity, who visited the event with a delegation of 38 members totaling more than half of the Spanish business representation, held a total of 585 meetings with companies and American institutions and of other countries present. In general, the balance of these meetings has been very positive, with the possibility of establishing future collaborations. In the contest, Asebio had two stands: one shared with the Spanish Institute of foreign trade (Icex) and genome Spain, which issued its activity in the domestic biotechnology market, and another dedicated to BioSpain 2010, the main Spanish biotechnology eventorganized by Asebio and Sodena, to be held between September 29 and October 1.

On the occasion of the 2010 BIO International Convention, ICEX, with the collaboration of the Office for economic and commercial Spain in Chicago, organized the Spain-U.S. Business Life Sciences and Health Conference, at the Instituto Cervantes. In this workshop, held on 3 may, and inaugurated by Miguel Sebastian, Minister of industry, reviewed investment opportunities for the Spanish of the life sciences sector in United States. An event that also intervened Carlos Buesa, Managing Director of Oryzon Genomics and Asebio Vice President, who made reference to the support of the central Government as the key to the evolution of the sector. Within the framework of the fair, Oryzon Genomics, Noscira (Zeltia group) and Araclon Biotech, three member companies of Asebio, had the opportunity to participate as speakers in a framed in the section of the fair International Case Studies, with the session ' PlaquesTangles and Beyond: Therapeutics and Diagnostics Avenues for Neurodegenerative Diseases in Spain'. As speakers were Carlos Buesa, Managing Director of Oryzon Genomics, Miguel Medina, director of research at Noscira, and Peter Pesini, head of laboratory of Araclon Biotech, highlighted his recent discoveries in the area of Alzheimer's disease (diagnostic kits, vaccines and new drugs).